Clinical-stage biopharmaceutical development (CNS therapeutics)
Strategic Profile
The company received notice of delisting from Nasdaq in October 2024 due to non-compliance with the minimum stockholder's equity requirement and began trading on the OTCQB. Despite regulatory headwinds, Seelos received grant funding from the Michael J. Fox Foundation to advance its lead gene therapy candidate SLS-004 for Parkinson's disease, signaling external validation of its pipeline.
Cyborg Score Rationale
Seelos faces significant financial and regulatory challenges, including Nasdaq delisting, negative equity, and minimal revenue. However, the company maintains clinical assets with external validation and potential in high-value indications (PTSD, Parkinson's, ALS). Early-stage biotech inherently carries execution risk.
Top Insights
(October 2024) Delisted from Nasdaq and transferred to OTCQB due to non-compliance with stockholder equity requirements
(June 2026) Multiple reverse stock splits (1-for-8 in May 2024; 1-for-16 in September 2024) indicate severe dilution and valuation pressure
SLS-002 (intranasal racemic ketamine) in clinical trials for acute suicidal ideation and PTSD; partnered with U.S. Army Medical Materiel Development Activity for M-PACT trial
SLS-004 CRISPR-based gene therapy for Parkinson's disease selected for Michael J. Fox Foundation grant; validates early-stage approach
Named Competitors
Perception Neuroscience — Psychedelic-assisted therapy for PTSD and depression
Arcus Biosciences (now acquired by Janssen) — Large pharma with programs in psychiatric and neurological disease
Spark Therapeutics — Gene therapy for inherited retinal diseases and other CNS applications
REGENXBIO — AAV gene therapy platform for neurological disorders
Recent Developments
(June 2026) Company trading OTC (SEELQ) with minimal market capitalization
(October 2024) Delisting announcement following failure to meet Nasdaq stockholder equity requirements